Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro

Mol Med Rep. 2020 Aug;22(2):1063-1071. doi: 10.3892/mmr.2020.11144. Epub 2020 May 14.

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. The angiotensin II type 1 receptor blockers, telmisartan and candesartan, are widely used antihypertensive drugs that inhibits cancer cell proliferation; however, its underlying mechanisms in mesenchymal tumors, including GIST, remains unknown. The present study aimed to investigate the effect of telmisartan on GIST‑T1 cells and its underlying mechanism. Telmisartan and candesartan inhibited the proliferation of these cells by blocking the G0 to G1 cell cycle transition, which was accompanied by a decrease in cell cycle‑related proteins such as cyclin D1. Furthermore, telmisartan exposure significantly altered microRNA expression in vitro. In conclusion, telmisartan suppressed human GIST cell proliferation by inducing cell cycle arrest in vitro.

Keywords: gastrointestinal stromal tumor; telmisartan; cyclin; angiotensin ii type 1 receptor blocker; apoptosis.

MeSH terms

  • AMP-Activated Protein Kinases / drug effects
  • AMP-Activated Protein Kinases / metabolism
  • Angiogenesis Inducing Agents / metabolism
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Antihypertensive Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Cycle Checkpoints / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Cyclin D1 / drug effects
  • Cyclin D1 / metabolism
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / pathology*
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / metabolism*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • MicroRNAs / drug effects
  • MicroRNAs / metabolism
  • Telmisartan / pharmacology*
  • Tissue Array Analysis

Substances

  • Angiogenesis Inducing Agents
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • CCND1 protein, human
  • MicroRNAs
  • Cyclin D1
  • AMP-Activated Protein Kinases
  • Telmisartan